Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Omega-3 fatty acids (OFAs) are essential macromolecules which are frequently used to provide nutritional support in cancer patients. They have been recognised as immunonutrients, as they play important role in strengthening the immune responses against various disease including cancer. OFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have shown great promise in cancer prevention and its management. Epidemiological studies have demonstrated a correlation between fish consumption and reduced cancer risk, evidence suggests that increased fish consumption is linked to a lower risk of cancer, potentially due to the high levels of bioactive fatty acids in fish. Experimental studies revealed that OFAs are capable of modulating cell signalling pathways, gene expression and influencing cell membrane composition, which can promote apoptosis and inhibition of cell proliferation. Moreover, antioxidant property of fatty acids has been reported in prevention of oxidative stress-induced DNA damage. Apart from anticancer properties OFAs have also shown good results in managing the cancer related complications such as inflammation, gastrointestinal reactions, and anorexia-cachexia syndrome. Several studies showed their efficacy in relieving cancer associated cachexia anorexia syndrome with significant improvements in weight loss. Moreover, OFA supplementation has shown antidepressant results and enhanced well-being in cancer individuals. Despite the promising effects of OFAs many challenges remain like optimal dose determination, variable impact across cancer types and the risks associated with high fatty acids intake. Further large scale randomized control trials (RCTs) are needed to strengthening the OFAs assisted cancer treatment.
Omega-3 fatty acids (OFAs) are essential macromolecules which are frequently used to provide nutritional support in cancer patients. They have been recognised as immunonutrients, as they play important role in strengthening the immune responses against various disease including cancer. OFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have shown great promise in cancer prevention and its management. Epidemiological studies have demonstrated a correlation between fish consumption and reduced cancer risk, evidence suggests that increased fish consumption is linked to a lower risk of cancer, potentially due to the high levels of bioactive fatty acids in fish. Experimental studies revealed that OFAs are capable of modulating cell signalling pathways, gene expression and influencing cell membrane composition, which can promote apoptosis and inhibition of cell proliferation. Moreover, antioxidant property of fatty acids has been reported in prevention of oxidative stress-induced DNA damage. Apart from anticancer properties OFAs have also shown good results in managing the cancer related complications such as inflammation, gastrointestinal reactions, and anorexia-cachexia syndrome. Several studies showed their efficacy in relieving cancer associated cachexia anorexia syndrome with significant improvements in weight loss. Moreover, OFA supplementation has shown antidepressant results and enhanced well-being in cancer individuals. Despite the promising effects of OFAs many challenges remain like optimal dose determination, variable impact across cancer types and the risks associated with high fatty acids intake. Further large scale randomized control trials (RCTs) are needed to strengthening the OFAs assisted cancer treatment.
The impaired function of the serotonin transporter (SERT) in humans has been linked to a higher risk of obesity and type 2 diabetes, especially as people age. Consuming a “Western diet” (WD), which is high in saturated fats, cholesterol, and sugars, can induce metabolic syndrome. Previous research indicated that mice carrying a targeted inactivation of the Sert gene (knockout, KO) and fed a WD display significant metabolic disturbances and behaviors reminiscent of ADHD. These abnormalities might be mediated via a dysfunction in insulin receptor (IR) signaling, which is also associated with adult ADHD. However, the impact of Sert deficiency on IR signaling and systemic metabolic changes has not been thoroughly explored. In this study, we conducted a detailed analysis of locomotor behavior in wild-type (WT) and KO mice fed a WD or control diet. We investigated changes in the blood metabolome and examined, via PCR, the expression of insulin receptor A and B isoforms and key regulators of their function in the brain. Twelve-month-old KO mice and their WT littermates were fed a WD for three weeks. Nuclear magnetic resonance spectroscopy analysis of plasma samples showed that KO mice on a WD had higher levels of lipids and lipoproteins and lower levels of glucose, lactate, alanine, valine, and isoleucine compared to other groups. SERT-KO mice on the control diet exhibited increased brain levels of both IR A and B isoforms, accompanied by a modest increase in the negative regulator ENPP. The KO mice also displayed anxiety-like behavior and reduced exploratory activity in an open field test. However, when the KO animals were fed a WD, the aberrant expression levels of IR isoforms in the KO mice and locomotor behavior were ameliorated indicating a complex interaction between genetic and dietary factors that might contribute to ADHD-like symptoms. Overall, our findings suggest that the lack of Sert leads to a unique metabolic phenotype in aged mice, characterized by dysregulated IR-related pathways. These changes are exacerbated by WD in the blood metabolome and are associated with behavioral abnormalities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.